Form 4: Gilead Sciences CFO Andrew Dickinson Sells 2,500 Shares Under 10b5-1 Trading Plan

Gilead Sciences' Chief Financial Officer, Andrew Dickinson, executed a sale of 2,500 shares of common stock at a price of $110.53 per share, according to a Form 4 filing with the SEC.

Summary

• Andrew D. Dickinson, the Chief Financial Officer of Gilead Sciences, Inc., sold 2,500 shares of common stock on March 17, 2025.
• The sale was executed at a price of $110.53 per share.
• The transaction was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on August 29, 2024.
• Following the transaction, Dickinson directly owns 170,674 shares of Gilead Sciences common stock.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transaction was pre-planned under a 10b5-1 trading plan and doesn't necessarily reflect a change in the CFO's outlook on the company.

Industry Context

Insider transactions are routinely monitored by investors as they can provide insights into management's perspective on the company's valuation and future prospects. However, sales under pre-arranged 10b5-1 plans are less indicative of immediate sentiment as they are scheduled in advance.

Stakeholder Impact

• The sale of shares by a high-ranking officer could be perceived negatively by some shareholders, although the existence of a 10b5-1 plan mitigates this concern.

Key Dates